AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study



Status:Recruiting
Healthy:No
Age Range:22 - 75
Updated:11/7/2018
Start Date:September 5, 2018
End Date:January 2020
Contact:Ornela Gjata
Email:Ornela.Gjata@bsci.com
Phone:(508)-683-4155

Use our guide to learn which trials are right for you!

A Multicenter, Single-arm Study of Endoscopic Ultrasound-Guided Drainage of Walled-off Pancreatic Necrosis With Lumen-Apposing Metal Stents

To demonstrate safety and effectiveness of lumen-apposing metal stents for resolution of
walled off pancreatic necrosis (WONs) in patients with WONs with solid component >30%.

This study is a prospective, single arm, multi-center trial. Treatment of up to 40 patients
will take place at up to 6 clinical centers. Patients who meet all eligibility criteria will
receive the AXIOS stent for up to 60 days stent indwell and 6 months follow-up after stent
removal.

Inclusion Criteria:

- Age between 22 and 75 years old

- Severe or moderately severe acute necrotizing pancreatitis, defined per the 2012
Revised Atlanta Classification.

- WON resulting from necrotizing pancreatitis per contrast-enhanced CT with the
following characteristics, per the 2012 Revised Atlanta Classification:

- Heterogeneous with liquid and non-liquid density with varying degrees of
loculations (some may appear homogeneous)

- Well defined wall

- Location-intrapancreatic and/or extrapancreatic

- Infected WON or symptomatic sterile WON Note: WON-related symptoms may include: pain,
fever, leukocytosis, failure to thrive or deterioration of overall heath score,
gastric outlet obstruction (GOO), weight loss, biliary obstructive symptoms, systemic
inflammatory response syndrome (SIRS), deteriorating organ function, chronic nausea,
lethargy, and inability to eat or gain weight

- Imaging suggestive of greater than 30% necrotic material

- WON ≥ 6cm in size

- Eligible for endoscopic intervention

- Acceptable candidate for endoscopic transluminal drainage

- Patient understands the study requirements and the treatment procedures and provides
written Informed Consent

- Patient is willing to comply with all specified follow-up evaluations, including
willingness to undergo a pre/post imaging study

Exclusion Criteria:

- Pseudocyst

- Cystic neoplasm

- Untreated Pseudoaneurysm > 1cm within the WON

- More than one WON clearly separated and requiring drainage

- WONs that require dual modality interventions (endoscopic and percutaneous) from the
beginning (i.e. deep paracolic space involvement that is inaccessible through the
central drainage access)

- Prior surgical, interventional radiology or endoscopic procedures for the treatment of
the WON

- Abnormal coagulation:

- INR > 1.5 and not correctable

- presence of a bleeding disorder

- platelets < 50,000/mm3

- Intervening gastric varices or unavoidable blood vessels within the access tract
(visible using endoscopy or endoscopic ultrasound)

- WON that poorly approximates the GI lumen (≥1cm away)

- Pericolic gutter necrosis

- Pelvic necrosis

- Prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium),
silicone or any other materials contacting the patient

- Female of childbearing potential with a positive pregnancy test prior to the procedure
or intends to become pregnant during the study

- Currently participating in another investigational drug or device study that has not
completed the primary endpoint or that clinically interferes with the endpoints of
this study
We found this trial at
5
sites
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
Principal Investigator: Raj J Shah, MD
Phone: 303-724-1862
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Christopher C Thompson, MD
Phone: 617-676-5928
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Field F Willingham, MD
Phone: 404-778-4024
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Jeffery J Easler, MD
Phone: 317-948-8104
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Barham K Abu Dayyeh, MD
Phone: 507-538-1700
?
mi
from
Rochester, MN
Click here to add this to my saved trials